Allergies News and Research

Latest Allergies News and Research

NIAID announces 14 grants for basic research to identify new HIV vaccine approaches

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.

22 Aug 2012

Sore throat treatment should be individually tailored

Throat discomfort may have a variety of causes and a range of symptoms, all of which should be considered before decisions about treatment are made, report researchers.

21 Aug 2012

Allergy transmission may be gender specific

Parents with allergies are more likely to pass them on to their same gender children than to children of the opposite gender, say researchers.

17 Aug 2012

CD4 T cells orchestrate inflammatory attack on the artery wall

Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system.

15 Aug 2012

Medicine brand choices: an interview with Dr Lynn Weekes

In Australia, people will only be offered a choice when the brands are bioequivalent, meaning they contain the same active ingredient (i.e. the chemical in the medicine that makes it work) and have been proven to work the same in the body.

15 Aug 2012

AstraZeneca enters agreement with Pfizer for OTC NEXIUM

Pfizer Inc. today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD).

14 Aug 2012

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

13 Aug 2012

Meritage commences OBS Phase 2 clinical trial for eosinophilic esophagitis

Meritage Pharma, Inc. announced that it has initiated a Phase 2 clinical trial to evaluate oral budesonide suspension (OBS) for the treatment of adolescents and young adults with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

13 Aug 2012

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Antigen Discovery, Inc. today announced that it has received a Phase II Small Business Innovation and Research award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens.

13 Aug 2012

Brain activity rapidly changes in olfactory regions following odor deprivation

Has a summer cold or mold allergy stuffed up your nose and dampened your sense of smell? We take it for granted that once our nostrils clear, our sniffers will dependably rebound and alert us to a lurking neighborhood skunk or a caramel corn shop ahead. That dependability is no accident. It turns out the brain is working overtime behind the scenes to make sure the sense of smell is just as sharp after the nose recovers.

13 Aug 2012

Breakthrough vaccine against deadly Nipah virus

A major breakthrough in the development of a highly effective vaccine against the deadly Nipah virus has been reported by a team of federal and university scientists. The results of their study, "A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge," will appear in Science Translational Medicine online.

10 Aug 2012

Allergies appear to lower brain tumor risk

Testing positive for immunoglobulin E, a biomarker of allergy, reduces a person’s risk for developing glioma, show study findings.

10 Aug 2012

University of Nevada researcher to optimize new rapid test for melioidosis

A new rapid test to diagnose melioidosis, a difficult infection to treat - and classified as a biothreat by the Centers for Disease Control and Prevention - is being optimized and tested by University of Nevada School of Medicine researcher David AuCoin.

9 Aug 2012

Cardionovum to introduce PROLIMUS Biograde system in Europe

Cardionovum GmbH announced today that it expects to launch in Europe in Q4 2012 a next-generation Sirolimus-eluting coronary stent system—PROLIMUS Biograde—which is designed to optimize long-term patient results. Unlike many state-of-the-art DES that are currently being marketed, PROLIMUS Biograde provides multiple pro-healing product features to promote early re-endothelialization.

9 Aug 2012

Elimination diet may help manage cow's milk protein allergy in infants

Cow's milk protein allergy (CMPA), although difficult to diagnose in young children, shows a causative relationship to otolaryngic symptoms. A new study in the August journal, Otolaryngology-Head and Neck Surgery suggests an elimination diet may help manage such conditions in children under two and reduce the need for more serious upper airway tests and interventions.

8 Aug 2012

Mylan receives final FDA approval for Montelukast Sodium Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair Tablets.

7 Aug 2012

High mold count signals dangerous air quality warning in Chicago

Chicago's mold count today is 125,000 plus - more than double the 50,000 threshold that signals a dangerous air quality warning. "Today's mold count is the highest I have recorded in more than 15 years," said Dr. Joseph Leija, who performs the Gottlieb Allergy Count, the official allergy count for the Midwest. "Midwesterners with sensitive respiratory systems will experience itchy throats, runny noses and feel generally rundown."

7 Aug 2012

NCH conducts workshop to teach participants how and when to use EpiPen

Many children with severe allergies carry injectable epinephrine (EpiPens) - syringes filled with epinephrine to delay an allergic reaction - but the EpiPens sometimes require the help of an adult to dispense. School nurses are often the only school officials authorized to handle medications, leaving the educators who are with the children most of the day untrained. According to doctors at Nationwide Children's Hospital, this lack of training is exactly what becomes most dangerous for children with severe allergies.

7 Aug 2012

Qualitest confirms launch of generic Singulair Tablets for asthma and allergic rhinitis

Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets, following the expiration of the last patent that provides Merck U.S. market exclusivity. Qualitest will begin shipping the product immediately. Montelukast Sodium Tablets are labeled for use in treating symptoms of asthma and allergic rhinitis.

6 Aug 2012

Common ragweed may induce airways irritation through terpenoids

Allergy to pollen of common ragweed is increasingly affecting patients and is second only to grass pollen in terms of incidence in the general population of many European countries.

6 Aug 2012